GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apex Biotechnology Corp (TPE:1733) » Definitions » EBIT

Apex Biotechnology (TPE:1733) EBIT : NT$130 Mil (TTM As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Apex Biotechnology EBIT?

Apex Biotechnology's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was NT$33 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$130 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Apex Biotechnology's annualized ROC % for the quarter that ended in Mar. 2024 was 3.89%. Apex Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 9.49%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Apex Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.28%.


Apex Biotechnology EBIT Historical Data

The historical data trend for Apex Biotechnology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apex Biotechnology EBIT Chart

Apex Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 172.57 120.89 197.47 204.97 145.35

Apex Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.28 34.42 49.36 13.29 33.28

Competitive Comparison of Apex Biotechnology's EBIT

For the Biotechnology subindustry, Apex Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apex Biotechnology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apex Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Apex Biotechnology's EV-to-EBIT falls into.



Apex Biotechnology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$130 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apex Biotechnology  (TPE:1733) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Apex Biotechnology's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=65.496 * ( 1 - 10.07% )/( (1554.35 + 1472.889)/ 2 )
=58.9005528/1513.6195
=3.89 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2297.004 - 298.74 - ( 443.914 - max(0, 383.354 - 1506.641+443.914))
=1554.35

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2333.93 - 401.349 - ( 459.692 - max(0, 498.708 - 1556.205+459.692))
=1472.889

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Apex Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=133.12/( ( (722.999 + max(738.291, 0)) + (712.791 + max(632.167, 0)) )/ 2 )
=133.12/( ( 1461.29 + 1344.958 )/ 2 )
=133.12/1403.124
=9.49 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(288.39 + 747.714 + 20.906) - (298.74 + 0 + 19.979)
=738.291

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(368.609 + 694.736 + 22.774) - (401.349 + 0 + 52.603)
=632.167

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Apex Biotechnology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=130.351/3044.222
=4.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apex Biotechnology EBIT Related Terms

Thank you for viewing the detailed overview of Apex Biotechnology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Apex Biotechnology (TPE:1733) Business Description

Traded in Other Exchanges
N/A
Address
No.7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp engages mainly in research, development, production, manufacturing and selling of biochemical testing instruments and its detection strips, and trade of products and components relevant to the core business. The company develops and markets biosensor-based blood glucose monitoring systems. The company manufactures non-invasive diagnostic technologies, IT-based telehealth care and molecular diagnostic and traditional Chinese medicine. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, HemoSmart GOLD hemoglobin screening system among others.

Apex Biotechnology (TPE:1733) Headlines

No Headlines